ADIA, Aberdeen lead $91M secondary block trade in Corona Remedies as ChrysCapital trims stake
What's the deal? A consortium of foreign and domestic institutional investors, led by Abu Dhabi Investment AuthorityDealroom has a profile for this one. Try Dealroom → (ADIA), bought a 7.3% stake in Indian pharma firm Corona Remedies for ₹777 crore (~$91M) through open market transactions.
Aberdeen Group and Factory Mutual Insurance Company joined ADIA on the foreign side. Domestic buyers included Aditya Birla Sun Life Mutual Fund, HDFC Mutual FundDealroom has a profile for this one. Try Dealroom →, WhiteOak Capital Mutual Fund, Invesco Mutual FundDealroom has a profile for this one. Try Dealroom →, Kotak Mahindra Mutual Fund, and others.
A total of 44.90 lakh (4.49 million) equity shares changed hands at an average price of ₹1,730 apiece. Corona Remedies' stock rose nearly 3% following the deal.
Why now? The shares came from a sell-side exit by ChrysCapital, the private equity firm that had backed Corona Remedies before it went public. ChrysCapital's affiliate Sepia Investments offloaded a 7.07% stake, cutting its holding from 19.76% to 12.69%. Anchor PartnersDealroom has a profile for this one. Try Dealroom → sold an additional 0.26%.
The deal marks a significant monetisation event for ChrysCapital — and a rare post-IPO secondary block trade large enough to draw sovereign wealth capital.
What could go wrong? A PE firm dumping a large stake can weigh on sentiment, even when heavyweight buyers step in. ChrysCapital still holds nearly 13%, and further sell-downs could create overhang pressure on the stock.
Corona Remedies, headquartered in Ahmedabad, operates in niche therapeutic areas — women's healthcare, cardio-diabeto, pain management, and urology — that are competitive and require sustained R&D spending to maintain margins.
The signal: ADIA's participation in a secondary block trade for a late-stage, mid-cap Indian pharma company underscores how sovereign wealth funds are increasingly tapping open-market transactions — rather than primary rounds — to gain exposure to India's pharmaceutical sector. The diversity of the buyer syndicate, spanning a sovereign wealth fund, a US insurance pension plan, and at least five major Indian mutual fund houses, suggests broad institutional confidence in Corona Remedies' niche therapeutic positioning despite the overhang of ChrysCapital's remaining ~13% stake.
